The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naive women with N0/N1 primary breast cancer [Elektronisk resurs]
-
Strand, Carina (författare)
-
Bak, Martin (författare)
-
Borgquist, Signe (författare)
-
Chebil, Gunilla (författare)
-
Falck, Anna-Karin (författare)
-
Fjällskog, Marie-Louise (författare)
-
Grabau, Dorthe (författare)
-
Hedenfalk, Ingrid (författare)
-
Jirström, Karin (författare)
-
Klintman, Marie (författare)
-
Malmström, Per (författare)
-
Olsson, Hans (författare)
-
Rydén, Lisa (författare)
-
Stål, Olle (författare)
-
Bendahl, Pär-Ola (författare)
-
Fernö, Mårten (författare)
-
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet (utgivare)
-
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet (utgivare)
- 2013
- Engelska.
-
Ingår i: SpringerPlus. ; 2
-
Läs hela texten
-
Läs hela texten
-
Läs hela texten
Sammanfattning
Ämnesord
Stäng
- Background: The aim was to confirm a previously defined prognostic index, combining a proliferation marker, histological grade, and estrogen receptor (ER) in different subsets of primary N0/N1 chemo-naive breast cancer patients. Methods/design: In the present study, including 1,854 patients, Ki67 was used in the index (KiGE), since it is the generally accepted proliferation marker in clinical routine. The low KiGE-group was defined as histological grade 1 patients and grade 2 patients which were ER-positive and had low Ki67 expression. All other patients made up the high KiGE-group. The KiGE-index separated patients into two groups with different prognosis. In multivariate analysis, KiGE was significantly associated with disease-free survival, when adjusted for age at diagnosis, tumor size and adjuvant endocrine treatment (hazard ratio: 3.5, 95% confidence interval: 2.6-4.7, P<0.0001). Discussion: We have confirmed a prognostic index based on a proliferation marker (Ki67), histological grade, and ER for identification of a low-risk group of patients with N0/N1 primary breast cancer. For this low-risk group constituting 57% of the patients, with a five-year distant disease-free survival of 92%, adjuvant chemotherapy will have limited effect and may be avoided.
Ämnesord
- Medical and Health Sciences (hsv)
- Clinical Medicine (hsv)
- Cancer and Oncology (hsv)
- Medicin och hälsovetenskap (hsv)
- Klinisk medicin (hsv)
- Cancer och onkologi (hsv)
Indexterm och SAB-rubrik
- Breast cancer
- Chemo-naive
- Ki67
- Prognostic index
- Proliferation
Inställningar
Hjälp
Beståndsinformation saknas